2020
DOI: 10.1089/thy.2019.0791
|View full text |Cite
|
Sign up to set email alerts
|

The De Novo Detection of Anti-Thyroglobulin Antibodies and Differentiated Thyroid Cancer Recurrence

Abstract: Background: The prevalence and clinical significance of de novo detection of anti-thyroglobulin antibodies (TgAbs) during the follow-up of patients with differentiated thyroid cancer (DTC) is unknown. Methods: We utilized the National Thyroid Cancer Treatment Cooperative Study registry . Patients registered after 1996 (n = 3318) were analyzed. We identified 1545 subjects who had available TgAb status (TgAb cohort) between years 1996 and 2012, of whom 1325 were TgAb negative at first postoperative follow-up tes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
8
1

Year Published

2020
2020
2025
2025

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 29 publications
1
8
1
Order By: Relevance
“…7,22 Of note, Yin et al recently reported the uncommon finding of de novo anti-Tg development occurring in approximately 5% of previously anti-Tg-negative DTC patients. 23 In this study, in all cases de novo anti-Tg antibodies appeared 2 years after structural recurrence. The authors speculated that recurrent Tg may be structurally different, thus more immunogenic leading to de novo anti-Tg appearance.…”
Section: Discussionsupporting
confidence: 49%
“…7,22 Of note, Yin et al recently reported the uncommon finding of de novo anti-Tg development occurring in approximately 5% of previously anti-Tg-negative DTC patients. 23 In this study, in all cases de novo anti-Tg antibodies appeared 2 years after structural recurrence. The authors speculated that recurrent Tg may be structurally different, thus more immunogenic leading to de novo anti-Tg appearance.…”
Section: Discussionsupporting
confidence: 49%
“…21 was published during the revisions of our study). Compared to the study by Yin et al., 21 we found a similar prevalence of de novo TgAbs (3.3% in our study considering only the sustained de novo TgAbs vs. 5%). We came to the same conclusion that de novo TgAbs development does not seem to be significantly associated with DTC structural recurrence, with respect to persistently TgAb-negative patients.…”
Section: Discussionmentioning
confidence: 88%
“…To the best of our knowledge, this is the second specifically designed study that has analyzed the prevalence of de novo TgAbs appearance and its clinical implications (the paper by Yin et al 21 was published during the revisions of our study). Compared to the study by Yin et al, 21 we found a similar prevalence of de novo TgAbs (3.3% in our study considering only the sustained de novo TgAbs vs. 5%). We came…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations